CYTOSORBENTS CORPORATION (CTSO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 26.65M USD | Gross Profit |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 10.57M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $26.65M | (m) | $10.57M | (m) |
| 2026-03-31 | $26.41M | (m) | $10.79M | (m) |
| 2025-12-31 | $26.49M | (m) | $10.57M | (m) |
| 2025-09-30 | $26.18M | (m) | $10.80M | (m) |
| 2025-06-30 | $24.77M | (m) | $11.34M | (m) |
| 2025-03-31 | $24.46M | (m) | $10.87M | (m) |
| 2024-12-31 | $25.13M | (m) | $10.47M | (m) |
| 2024-09-30 | $23.67M | (m) | $14.07M | (m) |
| 2024-06-30 | $23.99M | (m) | $13.17M | (m) |
| 2024-03-31 | $23.51M | (m) | $13.18M | (m) |
| 2023-12-31 | $22.39M | (m) | $13.96M | (m) |
| 2023-09-30 | $22.84M | (m) | $14.23M | (m) |
| 2023-06-30 | $20.85M | (m) | $15.52M | (m) |
| 2023-03-31 | $19.77M | (m) | $15.67M | (m) |
| 2022-12-31 | $20.73M | (m) | $13.96M | (m) |
| 2022-09-30 | $22.64M | (m) | $13.45M | (m) |
| 2022-06-30 | $26.32M | (m) | $11.41M | (m) |
| 2022-03-31 | $30.68M | (m) | $10.57M | (m) |
| 2021-12-31 | $32.12M | (m) | $11.05M | (m) |
| 2021-09-30 | $33.89M | (m) | $10.45M | (m) |
| 2021-06-30 | $34.25M | (m) | $10.88M | (m) |
| 2021-03-31 | $31.48M | (m) | $11.42M | (m) |
| 2020-12-31 | $29.95M | (m) | $11.05M | (m) |
| 2020-09-30 | $25.86M | (m) | $10.62M | (m) |
| 2020-06-30 | $22.60M | (m) | $9.43M | (m) |
| 2020-03-31 | $20.45M | (m) | $8.01M | (m) |
| 2019-12-31 | $17.59M | (m) | $7.36M | (m) |
| 2019-09-30 | $16.25M | (m) | $7.35M | (m) |
| 2019-06-30 | $15.54M | $23.25M | $7.71M | 66.84% |
| 2019-03-31 | $15.11M | $22.77M | $7.66M | 66.36% |
| 2018-12-31 | $15.01M | $22.50M | $7.49M | 66.72% |
| 2018-09-30 | $14.40M | $21.07M | (m) | 68.34% |
| 2018-06-30 | $13.02M | $19.15M | (m) | 67.96% |
| 2018-03-31 | $11.13M | $16.96M | (m) | 65.62% |
| 2017-12-31 | $9.63M | $15.15M | (m) | 63.58% |
| 2017-09-30 | $8.04M | $13.59M | (m) | 59.15% |
| 2017-06-30 | $7.18M | $12.18M | (m) | 58.95% |
| 2017-03-31 | $6.44M | $10.83M | (m) | 59.48% |
| 2016-12-31 | $5.57M | $9.53M | (m) | 58.50% |
| 2016-09-30 | $4.74M | $8.21M | (m) | 57.83% |
| 2016-06-30 | $4.00M | $7.14M | (m) | 56.07% |
| 2016-03-31 | $3.15M | $5.88M | (m) | 53.60% |
| 2015-12-31 | $2.58M | $4.79M | (m) | 53.82% |
| 2015-09-30 | $2.17M | $3.90M | (m) | 55.48% |
| 2015-06-30 | $2.15M | $3.72M | (m) | 57.69% |
| 2015-03-31 | $2.01M | $3.78M | (m) | 53.07% |
| 2014-12-31 | $1.99M | $4.12M | (m) | 48.24% |
| 2014-09-30 | $1.49M | $4.13M | (m) | 35.99% |
| 2014-06-30 | $1.06M | $3.85M | (m) | 27.54% |
| 2014-03-31 | $792.92K | $3.11M | (m) | 25.47% |
| 2013-12-31 | $511.10K | $2.42M | (m) | 21.10% |
| 2013-09-30 | $1.02M | $2.15M | (m) | 47.30% |
| 2013-06-30 | $1.12M | (m) | (m) | (m) |
| 2013-03-31 | $1.15M | (m) | (m) | (m) |
| 2012-12-31 | $1.02M | $1.34M | (m) | 76.22% |
| 2012-09-30 | $501.83K | $774.69K | (m) | 64.78% |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | $24.32K | $36.08K | (m) | 67.40% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |